ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nonstimulant ADHD Treatment Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-38K16874
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Nonstimulant ADHD Treatment Drugs Market Research Report 2024
BUY CHAPTERS

Global Nonstimulant ADHD Treatment Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-38K16874
Report
November 2025
Pages:122
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Eli Lilly
Takeda
Novartis
NEOS Therapeutics
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
CTFH

Nonstimulant ADHD Treatment Drugs Market

The global Nonstimulant ADHD Treatment Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Nonstimulant ADHD treatment drugs are an alternative to stimulant medications for managing Attention Deficit Hyperactivity Disorder (ADHD). These medications include substances like atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay). Unlike stimulants, which increase dopamine and norepinephrine levels rapidly, nonstimulants work more gradually by modulating neurotransmitters subtly over time. They are particularly useful for patients who may not respond well to stimulants, or who experience significant side effects. Nonstimulants are noted for their ability to improve concentration, decrease impulsivity, and reduce hyperactivity, with a lower potential for abuse. They can be a good option for individuals seeking a medication regimen with a different side effect profile or mechanism of action compared to traditional stimulant therapies.
From a downstream perspective, Hospital Pharmacy accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Nonstimulant ADHD Treatment Drugs leading manufacturers including Eli Lilly, Takeda, Novartis, Neos Therapeutics, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, CTFH, etc., dominate supply; the top five capture approximately % of global revenue, with Eli Lilly leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Nonstimulant ADHD Treatment Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Nonstimulant ADHD Treatment Drugs Market Report

Report Metric Details
Report Name Nonstimulant ADHD Treatment Drugs Market
Segment by Type
  • Atomoxitine
  • Guanfacine
  • Clonidine
  • Other
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Eli Lilly, Takeda, Novartis, Neos Therapeutics, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, CTFH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Nonstimulant ADHD Treatment Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Nonstimulant ADHD Treatment Drugs Market report?

Ans: The main players in the Nonstimulant ADHD Treatment Drugs Market are Eli Lilly, Takeda, Novartis, Neos Therapeutics, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, CTFH

What are the Application segmentation covered in the Nonstimulant ADHD Treatment Drugs Market report?

Ans: The Applications covered in the Nonstimulant ADHD Treatment Drugs Market report are Hospital Pharmacy, Retail Pharmacy

What are the Type segmentation covered in the Nonstimulant ADHD Treatment Drugs Market report?

Ans: The Types covered in the Nonstimulant ADHD Treatment Drugs Market report are Atomoxitine, Guanfacine, Clonidine, Other

1 Study Coverage
1.1 Introduction to Nonstimulant ADHD Treatment Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nonstimulant ADHD Treatment Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Atomoxitine
1.2.3 Guanfacine
1.2.4 Clonidine
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Nonstimulant ADHD Treatment Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Nonstimulant ADHD Treatment Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Nonstimulant ADHD Treatment Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Nonstimulant ADHD Treatment Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Nonstimulant ADHD Treatment Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Atomoxitine Market Size by Players
3.3.2 Guanfacine Market Size by Players
3.3.3 Clonidine Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Nonstimulant ADHD Treatment Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Nonstimulant ADHD Treatment Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Nonstimulant ADHD Treatment Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Nonstimulant ADHD Treatment Drugs Market Size by Type (2020-2031)
6.4 North America Nonstimulant ADHD Treatment Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Nonstimulant ADHD Treatment Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Nonstimulant ADHD Treatment Drugs Market Size by Type (2020-2031)
7.4 Europe Nonstimulant ADHD Treatment Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Nonstimulant ADHD Treatment Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Nonstimulant ADHD Treatment Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Nonstimulant ADHD Treatment Drugs Market Size by Type (2020-2031)
9.4 Central and South America Nonstimulant ADHD Treatment Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Nonstimulant ADHD Treatment Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Nonstimulant ADHD Treatment Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Nonstimulant ADHD Treatment Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Nonstimulant ADHD Treatment Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.1.4 Eli Lilly Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.1.5 Eli Lilly Nonstimulant ADHD Treatment Drugs Revenue by Product in 2024
11.1.6 Eli Lilly Nonstimulant ADHD Treatment Drugs Revenue by Application in 2024
11.1.7 Eli Lilly Nonstimulant ADHD Treatment Drugs Revenue by Geographic Area in 2024
11.1.8 Eli Lilly Nonstimulant ADHD Treatment Drugs SWOT Analysis
11.1.9 Eli Lilly Recent Developments
11.2 Takeda
11.2.1 Takeda Corporation Information
11.2.2 Takeda Business Overview
11.2.3 Takeda Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.2.4 Takeda Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Takeda Nonstimulant ADHD Treatment Drugs Revenue by Product in 2024
11.2.6 Takeda Nonstimulant ADHD Treatment Drugs Revenue by Application in 2024
11.2.7 Takeda Nonstimulant ADHD Treatment Drugs Revenue by Geographic Area in 2024
11.2.8 Takeda Nonstimulant ADHD Treatment Drugs SWOT Analysis
11.2.9 Takeda Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.3.4 Novartis Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Novartis Nonstimulant ADHD Treatment Drugs Revenue by Product in 2024
11.3.6 Novartis Nonstimulant ADHD Treatment Drugs Revenue by Application in 2024
11.3.7 Novartis Nonstimulant ADHD Treatment Drugs Revenue by Geographic Area in 2024
11.3.8 Novartis Nonstimulant ADHD Treatment Drugs SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Neos Therapeutics
11.4.1 Neos Therapeutics Corporation Information
11.4.2 Neos Therapeutics Business Overview
11.4.3 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.4.4 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.4.5 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Revenue by Product in 2024
11.4.6 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Revenue by Application in 2024
11.4.7 Neos Therapeutics Nonstimulant ADHD Treatment Drugs Revenue by Geographic Area in 2024
11.4.8 Neos Therapeutics Nonstimulant ADHD Treatment Drugs SWOT Analysis
11.4.9 Neos Therapeutics Recent Developments
11.5 Amneal Pharmaceuticals
11.5.1 Amneal Pharmaceuticals Corporation Information
11.5.2 Amneal Pharmaceuticals Business Overview
11.5.3 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.5.4 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Revenue by Product in 2024
11.5.6 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Revenue by Application in 2024
11.5.7 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs Revenue by Geographic Area in 2024
11.5.8 Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs SWOT Analysis
11.5.9 Amneal Pharmaceuticals Recent Developments
11.6 Noven Pharmaceuticals
11.6.1 Noven Pharmaceuticals Corporation Information
11.6.2 Noven Pharmaceuticals Business Overview
11.6.3 Noven Pharmaceuticals Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.6.4 Noven Pharmaceuticals Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Noven Pharmaceuticals Recent Developments
11.7 Purdue Parma
11.7.1 Purdue Parma Corporation Information
11.7.2 Purdue Parma Business Overview
11.7.3 Purdue Parma Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.7.4 Purdue Parma Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Purdue Parma Recent Developments
11.8 CTFH
11.8.1 CTFH Corporation Information
11.8.2 CTFH Business Overview
11.8.3 CTFH Nonstimulant ADHD Treatment Drugs Product Features and Attributes
11.8.4 CTFH Nonstimulant ADHD Treatment Drugs Revenue and Gross Margin (2020-2025)
11.8.5 CTFH Recent Developments
12 Nonstimulant ADHD Treatment DrugsIndustry Chain Analysis
12.1 Nonstimulant ADHD Treatment Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Nonstimulant ADHD Treatment Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Nonstimulant ADHD Treatment Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Eli Lilly
Takeda
Novartis
NEOS Therapeutics
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
CTFH
List of Tables
 Table 1. Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Nonstimulant ADHD Treatment Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Nonstimulant ADHD Treatment Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Nonstimulant ADHD Treatment Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Nonstimulant ADHD Treatment Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonstimulant ADHD Treatment Drugs as of 2024)
 Table 11. Global Nonstimulant ADHD Treatment Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Nonstimulant ADHD Treatment Drugs Companies Headquarters
 Table 13. Global Nonstimulant ADHD Treatment Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Nonstimulant ADHD Treatment Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Nonstimulant ADHD Treatment Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Nonstimulant ADHD Treatment Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Nonstimulant ADHD Treatment Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Nonstimulant ADHD Treatment Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Nonstimulant ADHD Treatment Drugs Growth Accelerators and Market Barriers
 Table 25. North America Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Nonstimulant ADHD Treatment Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Nonstimulant ADHD Treatment Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Nonstimulant ADHD Treatment Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Nonstimulant ADHD Treatment Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Nonstimulant ADHD Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Eli Lilly Corporation Information
 Table 35. Eli Lilly Description and Major Businesses
 Table 36. Eli Lilly Product Features and Attributes
 Table 37. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Eli Lilly Revenue Proportion by Product in 2024
 Table 39. Eli Lilly Revenue Proportion by Application in 2024
 Table 40. Eli Lilly Revenue Proportion by Geographic Area in 2024
 Table 41. Eli Lilly Nonstimulant ADHD Treatment Drugs SWOT Analysis
 Table 42. Eli Lilly Recent Developments
 Table 43. Takeda Corporation Information
 Table 44. Takeda Description and Major Businesses
 Table 45. Takeda Product Features and Attributes
 Table 46. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Takeda Revenue Proportion by Product in 2024
 Table 48. Takeda Revenue Proportion by Application in 2024
 Table 49. Takeda Revenue Proportion by Geographic Area in 2024
 Table 50. Takeda Nonstimulant ADHD Treatment Drugs SWOT Analysis
 Table 51. Takeda Recent Developments
 Table 52. Novartis Corporation Information
 Table 53. Novartis Description and Major Businesses
 Table 54. Novartis Product Features and Attributes
 Table 55. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Novartis Revenue Proportion by Product in 2024
 Table 57. Novartis Revenue Proportion by Application in 2024
 Table 58. Novartis Revenue Proportion by Geographic Area in 2024
 Table 59. Novartis Nonstimulant ADHD Treatment Drugs SWOT Analysis
 Table 60. Novartis Recent Developments
 Table 61. Neos Therapeutics Corporation Information
 Table 62. Neos Therapeutics Description and Major Businesses
 Table 63. Neos Therapeutics Product Features and Attributes
 Table 64. Neos Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Neos Therapeutics Revenue Proportion by Product in 2024
 Table 66. Neos Therapeutics Revenue Proportion by Application in 2024
 Table 67. Neos Therapeutics Revenue Proportion by Geographic Area in 2024
 Table 68. Neos Therapeutics Nonstimulant ADHD Treatment Drugs SWOT Analysis
 Table 69. Neos Therapeutics Recent Developments
 Table 70. Amneal Pharmaceuticals Corporation Information
 Table 71. Amneal Pharmaceuticals Description and Major Businesses
 Table 72. Amneal Pharmaceuticals Product Features and Attributes
 Table 73. Amneal Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Amneal Pharmaceuticals Revenue Proportion by Product in 2024
 Table 75. Amneal Pharmaceuticals Revenue Proportion by Application in 2024
 Table 76. Amneal Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 77. Amneal Pharmaceuticals Nonstimulant ADHD Treatment Drugs SWOT Analysis
 Table 78. Amneal Pharmaceuticals Recent Developments
 Table 79. Noven Pharmaceuticals Corporation Information
 Table 80. Noven Pharmaceuticals Description and Major Businesses
 Table 81. Noven Pharmaceuticals Product Features and Attributes
 Table 82. Noven Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Noven Pharmaceuticals Recent Developments
 Table 84. Purdue Parma Corporation Information
 Table 85. Purdue Parma Description and Major Businesses
 Table 86. Purdue Parma Product Features and Attributes
 Table 87. Purdue Parma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Purdue Parma Recent Developments
 Table 89. CTFH Corporation Information
 Table 90. CTFH Description and Major Businesses
 Table 91. CTFH Product Features and Attributes
 Table 92. CTFH Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. CTFH Recent Developments
 Table 94. Raw Materials Key Suppliers
 Table 95. Distributors List
 Table 96. Market Trends and Market Evolution
 Table 97. Market Drivers and Opportunities
 Table 98. Market Challenges, Risks, and Restraints
 Table 99. Research Programs/Design for This Report
 Table 100. Key Data Information from Secondary Sources
 Table 101. Key Data Information from Primary Sources


List of Figures
 Figure 1. Nonstimulant ADHD Treatment Drugs Product Picture
 Figure 2. Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Atomoxitine Product Picture
 Figure 4. Guanfacine Product Picture
 Figure 5. Clonidine Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Nonstimulant ADHD Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Hospital Pharmacy
 Figure 9. Retail Pharmacy
 Figure 10. Nonstimulant ADHD Treatment Drugs Report Years Considered
 Figure 11. Global Nonstimulant ADHD Treatment Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Nonstimulant ADHD Treatment Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Region (2020-2031)
 Figure 15. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Atomoxitine Revenue Market Share by Player in 2024
 Figure 18. Guanfacine Revenue Market Share by Player in 2024
 Figure 19. Clonidine Revenue Market Share by Player in 2024
 Figure 20. Other Revenue Market Share by Player in 2024
 Figure 21. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Type (2020-2031)
 Figure 22. Global Nonstimulant ADHD Treatment Drugs Revenue Market Share by Application (2020-2031)
 Figure 23. North America Nonstimulant ADHD Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 24. North America Top 5 Players Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) in 2024
 Figure 25. North America Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 26. North America Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 27. US Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 28. Canada Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 29. Mexico Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 30. Europe Nonstimulant ADHD Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. Europe Top 5 Players Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) in 2024
 Figure 32. Europe Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 33. Europe Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 34. Germany Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 35. France Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 36. U.K. Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 37. Italy Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 38. Russia Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Nonstimulant ADHD Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Top 8 Players Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) in 2024
 Figure 41. Asia-Pacific Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Asia-Pacific Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Indonesia Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. Japan Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 45. South Korea Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. Australia Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. India Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. Indonesia Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. Vietnam Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Malaysia Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. Philippines Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. Singapore Nonstimulant ADHD Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 53. Central and South America Nonstimulant ADHD Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Central and South America Top 5 Players Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) in 2024
 Figure 55. Central and South America Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 56. Central and South America Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Brazil Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 58. Argentina Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 59. Middle East and Africa Nonstimulant ADHD Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Middle East and Africa Top 5 Players Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) in 2024
 Figure 61. South America Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 62. Middle East and Africa Nonstimulant ADHD Treatment Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 63. GCC Countries Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 64. Israel Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 65. Egypt Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 66. South Africa Nonstimulant ADHD Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 67. Nonstimulant ADHD Treatment Drugs Industry Chain Mapping
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global ADHD Drug Treatment Market Research Report 2024
ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adult ADHD Treatment Market Research Report 2024
Global Psychostimulants Market Research Report 2024
Global Methylphenidate for ADHD Treatment Market Research Report 2024
Global Children ADHD Treatment Market Research Report 2024
Global Atomoxetine Hydrochloride Capsules Market Research Report 2024
Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025
Global Anti Adhd Supplements Market Research Report 2024
Attention Deficit Hyperactivity Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global ADHD Medications Market Insights Forecast to 2030
Global Guanfacine Extended Release Pill Market Research Report 2024
Global Attention deficit Hyperactivity Disorder ADHD Therapeutics Market Research Report 2024
Global Attention Deficit Hyperactivity Disorder ADHD Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Global Attention Deficit Hyperactivity Disorder ADHD Medications Market Research Report 2024
ADHD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Dextroamphetamine Sulfate API Market Research Report 2025
Methylphenidate Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Attention Deficit Hyperactivity Disorder ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attention Deficit Hyperactivity Disorder Treatment Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions